Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.33 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.33 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.33 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
| ▸ | IL1RN | P18510 | 1/20 | 0.30 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.30 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.30 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7335718 | 0.98 | ACHE (0.39) | ACHES1PR1S1PR2S1PR4S1PR3 | |
| SCHEMBL8972697 | 0.98 | ACHE (0.36) | ACHES1PR1S1PR2S1PR4S1PR3 | |
| Hydrochloric Acid SCHEMBL7344687 | 0.79 | — | — | |
| SCHEMBL21447846 | 0.76 | ACHE (0.44) | ACHES1PR1S1PR2S1PR4S1PR3 | |
| SCHEMBL332173 | 0.70 | ACHE (0.37) | ACHE | |
| SCHEMBL333101 | 0.70 | ESR1 (0.31) | — | |
| SCHEMBL1150855 | 0.70 | DRD2 (0.53) | ACHECYP11B1CYP11B2DRD2DRD3 | |
| SCHEMBL17702023 | 0.70 | DRD2 (0.53) | ACHECYP11B1CYP11B2DRD2DRD3 | |
| SCHEMBL4666253 | 0.70 | DRD2 (0.53) | ACHECYP11B1CYP11B2DRD2DRD3 | |
| SCHEMBL193434 | 0.70 | HTR2C (0.45) | ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120301542-A1 | EXTENDED RELEASE FORMULATIONS OF RASAGILINE AND USES THEREOF | PHARMA TWO B LTD. (IL) | 2012-11-29 | — | — | US | claimed |
| CN-102791258-A | Extended release formulations of rasagiline and uses thereof | PHARMA TWO B LTD | 2012-11-21 | — | — | CN | claimed |
| EP-1686973-A4 | COMPOSITIONS AND METHODS FOR TREATMENT OF CARDIOVASCULAR DISORDERS AND DISEASES | TECHNION RES & DEV FOUNDATION (IL) | 2009-03-25 | — | — | EP | claimed |
| US-20080090915-A1 | METHOD FOR PREVENTING OR ATTENUATING ANTHRACYCLINE-INDUCED CARDIOTOXICITY | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2008-04-17 | — | — | US | claimed |
| US-20070082958-A1 | Methods for treatment of renal failure | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2007-04-12 | — | — | US | claimed |
| US-20070078172-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2007-04-05 | — | — | US | claimed |
| WO-2006138475-A2 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2006-12-28 | — | — | WO | claimed |
| US-20060287401-A1 | Methods for treatment of cardiovascular disorders and diseases | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2006-12-21 | — | — | US | claimed |
| EP-1686973-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF CARDIOVASCULAR DISORDERS AND DISEASES | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION, LTD. (IL) | 2006-08-09 | — | — | EP | claimed |
| US-20050171210-A1 | Compositions and methods for treatment of cardiovascular disorders and diseases | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2005-08-04 | — | — | US | claimed |
| WO-2005051371-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF CARDIOVASCULAR DISORDERS AND DISEASES | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) | 2005-06-09 | — | — | WO | claimed |
| CN-1038928-C | Mono-fluorinated derivatives of N-propargyl-1-aminoindan and their use as inhibitors of monoamine oxidase | TEVA PHARMA (NL) | 1998-07-01 | — | — | CN | claimed |
| EP-0538134-B1 | Mono-fluorinated derivatives of N-propargyl-1-aminoindan and their use as inhibitors of monoamine oxidase | TEVA PHARMA (IL) | 1997-03-12 | — | — | EP | claimed |
| US-5486541-A | FOR TREATING PARKINSON*S DISEASE, MEMORY DISORDERS, ALZHEIMER*S DISEASE, DEPRESSION OR HYPERACTIVE SYNDROME | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1996-01-23 | — | — | US | claimed |
| EP-0538134-A2 | Mono-fluorinated derivatives of N-propargyl-1-aminoindan and their use as inhibitors of monoamine oxidase | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1993-04-21 | — | — | EP | claimed |
| JP-5262701-A | — | — | None | — | — | JP | disclosed |
| EP-3517103-A1 | EXTENDED RELEASE FORMULATIONS OF RASAGILINE AND USES THEREOF | Pharma Two B Ltd. (IL) | 2019-07-31 | — | — | EP | disclosed |
| JP-H05262701-A | MONOFLUORINATED DERIVATIVE OF N-PROPARGYL-1-AMINOINDAN, MEDICINE USING THE SAME AS EFFECTIVE COMPONENT, AND PRODUCTION OF THE DERIVATIVE | TEVA PHARMACEUT IND LTD | 1993-10-12 | — | — | JP | disclosed |
| CN-1073427-A | Phenyl ring list fluorizated N-propargyl-1-aminoidan reaches the selective depressant as monoamine oxidase (MAO) | TEVA PHARMA (IL) | 1993-06-23 | — | — | CN | disclosed |
| EP-0538134-A2 | Mono-fluorinated derivatives of N-propargyl-1-aminoindan and their use as inhibitors of monoamine oxidase | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1993-04-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078172-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | MAOB, MAOA, GPR119 | ACHE 639/4885S1PR1 2379/4885S1PR2 2341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.